Krystal Biotech
KRYS
154 hedge funds and large institutions have $1.62B invested in Krystal Biotech in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 62 increasing their positions, 50 reducing their positions, and 10 closing their positions.
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
24% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 50
12% more capital invested
Capital invested by funds: $1.45B → $1.62B (+$175M)
4% more funds holding
Funds holding: 148 → 154 (+6)
0.06% more ownership
Funds ownership: 81.12% → 81.18% (+0.06%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
73% less call options, than puts
Call options by funds: $5.68M | Put options by funds: $21.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$10M |
| 2 |
BlackRock
New York
|
+$9.97M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.83M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$4.9M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$3.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$52.1M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$8.87M |
| 3 |
AG
Artal Group
Luxembourg
|
-$7.42M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$7.29M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.07M |
KRYS Hedge Fund Activity: Q4 2022 in Review
154 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q4 2022, worth a combined $1.62B — up 12% from $1.45B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new KRYS positions and 10 closed out — a net gain of 8 holders — while 62 added to existing stakes and 50 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $10M. The largest seller was Point72 Asset Management, cutting an estimated $52.1M.
- 154 institutional investors held Krystal Biotech (KRYS) as of Q4 2022, up from 148 in Q3 2022.
- Funds reported $1.62B of Krystal Biotech stock for Q4 2022, up 12% quarter-over-quarter.
- 18 funds opened new Krystal Biotech positions in Q4 2022 and 10 closed out, a net change of +8 holders.
- The largest Krystal Biotech buyer in Q4 2022 was Avoro Capital Advisors, an estimated $10M added.
- The largest Krystal Biotech seller in Q4 2022 was Point72 Asset Management, an estimated $52.1M sold.
Based on aggregated 13F filings for Q4 2022.